Shares of Biogen, a US biotech company, trade around 50% higher in premarket today. Shares rally following results of an Alzheimer drug (Lecanemab) trial that Biogen developed along with Eisai, Japanese pharmaceutical company. Results showed that the pace of cognitive decline in patients who received Lecanemab dropped by 27% over 18 months compared to patients who received placebo. This is massive as it is the first drug to show effectiveness against Alzheimer in a definitive, large-scale trial. While the company noted that some side effects occurred, it also said that they were rarely severe.
Biogen trades around 50% higher in premarket today. Weekly chart. Source: xStation5
Meta Announces Its Own AI Chips. Is the Era of Full Dependence on NVIDIA Slowly Coming to an End?
Vodafone shares surge 13% after Xavier Niel's £4.4 billion investment. What's next for the stock?
🚩 Apollo Global warns on AI: Has the market become too optimistic?
Stock of the Week: Seagate Technology. How an old technology found a new role in the era of artificial intelligence